Fetal/Infant Origins of Adult Vascular Disease.
PMID: 32129165 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 3, 2020 Category: Drugs & Pharmacology Authors: Paraskevas KI, Briana DD, Malamitsi-Puchner A, Mikhailidis DP Tags: Curr Vasc Pharmacol Source Type: research

Assessment and management of volume overload among patients on chronic dialysis.
Abstract Volume overload is the most common complication in end-stage renal disease (ESRD) patients, being directly related to numerous complications including resistant hypertension, cardiac hypertrophy, congestive heart failure or arterial stiffness, among others. Therefore, volume overload is now considered an important risk factor for hard outcomes, like all-cause or cardiovascular mortality. Relying solely on clinical examination for assessing volume overload in ESRD patients lacks sensitivity and specificity. Numerous efforts have been made to identify new methods that could objectively assess volume status;...
Source: Current Vascular Pharmacology - February 23, 2020 Category: Drugs & Pharmacology Authors: Covic A, Siriopol D Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular effects of biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Abstract The risk of cardiovascular (CV) disease is increased among patients with systemic autoimmune rheumatic diseases and remains an underserved area of medical need. Although traditional risk factors for CV disease, such as hypertension, smoking, dyslipidemia and obesity contribute to endothelial dysfunction in rheumatoid arthritis (RA), they are not enough on their own to explain the observed excess CV risk. Rather, systemic inflammation seems to play a pivotal role in both disease states. With a view to the inflammatory process in autoimmune diseases, scientific interest has focused on recently introduced bi...
Source: Current Vascular Pharmacology - February 12, 2020 Category: Drugs & Pharmacology Authors: Drakopoulou M, Soulaidopoulos S, Oikonomou G, Toutouzas K, Tousoulis D Tags: Curr Vasc Pharmacol Source Type: research

Pharmacological Management of Type 2 Diabetes Complications.
PMID: 32013814 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - February 6, 2020 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos K, Stavropoulos K, Athyros VG Tags: Curr Vasc Pharmacol Source Type: research

Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice.
CONCLUSION: Pharmaceutical approach of CVD in T2DM is multilevel and complex. Drug classes featuring pleiotropic effects may boost our armamentarium in the fight against CVD. PMID: 32013815 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - February 6, 2020 Category: Drugs & Pharmacology Authors: Patoulias D, Stavropoulos K, Imprialos K, Athyros V, Doumas M, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular disease in the Systemic Vasculitides.
Abstract The vasculitides are a heterogeneous group of disorders, characterized by inflammatory cell infiltration and necrosis of blood vessels that cause vascular obstruction or aneurysm formation, affecting various organs such as lungs, kidneys, skin and joints. Cardiac involvement is commonly encountered in primary systemic vasculitis and it is associated with increased morbidity and mortality. Depending on the dominant pathophysiological mechanism, heart complications may manifest in different ways, including myocardial ischemia due to impaired micro- or macrovascular circulation, progressive heart failure fol...
Source: Current Vascular Pharmacology - January 28, 2020 Category: Drugs & Pharmacology Authors: Soulaidopoulos S, Madenidou AV, Daoussis D, Melissaropoulos K, Mavrogeni S, Kitas G, Dimitroulas T Tags: Curr Vasc Pharmacol Source Type: research

Primary Sj ögren's Syndrome and Cardiovascular Disease.
Primary Sjögren's Syndrome and Cardiovascular Disease. Curr Vasc Pharmacol. 2020 Jan 29;: Authors: Melissaropoulos K, Bogdanos D, Dimitroulas T, Sakkas LI, Kitas GD, Daoussis D Abstract Sjögren's syndrome is a rheumatic autoimmune disease that primarily affects middle-aged women and runs a slowly progressing course with sicca symptoms being the prevalent manifestation. Premature atherosclerosis and increased cardiovascular (CV) morbidity and mortality is frequently encountered in rheumatic diseases characterized by significant systemic inflammation, such as the inflammatory arthritides, syst...
Source: Current Vascular Pharmacology - January 28, 2020 Category: Drugs & Pharmacology Authors: Melissaropoulos K, Bogdanos D, Dimitroulas T, Sakkas LI, Kitas GD, Daoussis D Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular consequences of autoimmune rheumatic diseases.
CARDIOVASCULAR CONSEQUENCES OF AUTOIMMUNE RHEUMATIC DISEASES. Curr Vasc Pharmacol. 2020 Jan 27;: Authors: Atzeni F, Nucera V, Gerratana E, Fiorenza A, Gianturco L, Corda M, Sarzi-Puttini P Abstract The increased risk of cardiovascular disease (CVD) among patients with autoimmune rheumatic dis-eases such as rheumatoid arthritis, spondyloarthritis and systemic lupus erythematosus has been exten-sively documented. Sub-clinical atherosclerosis can be assessed using various non-invasive imaging techniques. However, the mechanisms underlying the greater risk of atherosclerotic CVD in patients with autoimmun...
Source: Current Vascular Pharmacology - January 26, 2020 Category: Drugs & Pharmacology Authors: Atzeni F, Nucera V, Gerratana E, Fiorenza A, Gianturco L, Corda M, Sarzi-Puttini P Tags: Curr Vasc Pharmacol Source Type: research

Novel Biomarkers/Predictors of Cardiovascular Disease and Cardiovascular Events.
on; P PMID: 31965944 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 20, 2020 Category: Drugs & Pharmacology Authors: Paraskevas KI, Ježovnik MK, Poredoš P Tags: Curr Vasc Pharmacol Source Type: research

Familial Hypercholesterolaemia Registry in the MENA Region.
PMID: 31880238 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 29, 2019 Category: Drugs & Pharmacology Authors: Kolovou G, Watts GF Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular Disease in Systemic Lupus Erythematosus: recent data on epidemiology, risk factors and prevention.
CONCLUSION: SLE patients warrant regular assessment of their cardiovascular risk with prompt initiation of general and disease-specific risk-lowering strategies. Other: Further studies will be required regarding the use of non-invasive tools and biomarkers for cardiovascular assessment and of risk-lowering strategies tailored to SLE patients. PMID: 31880245 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 25, 2019 Category: Drugs & Pharmacology Authors: Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G Tags: Curr Vasc Pharmacol Source Type: research

Uric acid in metabolic and cerebrovascular disorders: a review.
CONCLUSION: UA, which is associated with arterial hypertension and cardiovascular diseases, represents one of the indicators of oxidative homeostasis. Increasing concentrations represent a status of active inflammation which is observed with metabolic and cerebrovascular diseases. PMID: 31845632 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 16, 2019 Category: Drugs & Pharmacology Authors: Cortese F, Scicchitano P, Meliota G, Giordano P, Ciccone MM Tags: Curr Vasc Pharmacol Source Type: research

Screening for and Optimal Management of Small Abdominal Aortic Aneurysms: The Quest Continues.
PMID: 31769359 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - November 25, 2019 Category: Drugs & Pharmacology Authors: Paraskevas KI, Eckstein HH, Nicolaides AN, Geroulakos G Tags: Curr Vasc Pharmacol Source Type: research

Osteoprotegerin and Osteopontin Serum Levels are Associated with Vascular Function and Inflammation in Coronary Artery Disease Patients.
Abstract BACKGROUND: Osteoprotegerin and osteopontin have recently emerged as key factors in both vascular remodelling and atherosclerosis progression. Interleukin-6 (IL-6) is an inflammatory cytokine with a key role in atherosclerosis. The relationship of osteoprotegerin, osteopontin, and IL-6 serum levels with endothelial function and arterial stiffness was evaluated in patients with coronary artery disease (CAD). METHODS: We enrolled 219 patients with stable CAD and 112 control subjects. Osteoprotegerin, osteopontin and IL-6 serum levels were measured using an ELISA assay. Endothelial function was evaluate...
Source: Current Vascular Pharmacology - October 20, 2019 Category: Drugs & Pharmacology Authors: Maniatis K, Siasos G, Oikonomou E, Vavuranakis M, Zaromytidou M, Mourouzis K, Paraskevopoulos T, Charalambous G, Papavassiliou AG, Tousoulis D Tags: Curr Vasc Pharmacol Source Type: research

Pre- and Post-conditioning in Cardiovascular Surgery.
Abstract PMID: 31599710 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 12, 2019 Category: Drugs & Pharmacology Authors: Guerrero Orriach JL, Ramirez-Fernandez A Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular risk of synthetic, non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Abstract Patients with rheumatoid diseases have an increased risk of CVD and CVD-related death compared with the general population. Both the traditional cardiovascular risk factors and systemic inflammation are contributors to this phenomenon. This review examines the available evidence about the effects of synthetic, non-biologic disease-modifying antirheumatic drugs (DMARDs) in CVD risk. This is an important issue for clinicians when deciding on individual treatment plans in patients with rheumatic diseases. Evidence suggests that synthetic, non-biologic DMARDs such as methotrexate, sulfosalazine, hydroxychloro...
Source: Current Vascular Pharmacology - September 29, 2019 Category: Drugs & Pharmacology Authors: Mourouzis IS, Manolis AS, Pantos C Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular Disease in Antiphospholipid Syndrome.
Abstract Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by venous, arterial or microvascular thrombosis or obstetrical events in the presence of persistently positive antiphospholipid antibodies and constitutes a major cause of cardiovascular events in young people. Τhis review aims to highlight the pathophysiology of cardiovascular complications in patients with APS and possible treatment options. Patients with APS have endothelial dysfunction, accelerated proliferation and hyperplasia, atherogenesis, platelet activation and aggregation, inflammatory products secretion and coag...
Source: Current Vascular Pharmacology - August 28, 2019 Category: Drugs & Pharmacology Authors: Polytarchou K, Varvarousis D, Manolis AS Tags: Curr Vasc Pharmacol Source Type: research

Effects of Pregnancy-Induced Insulin Resistance on the Fetus and the Future Development of Metabolic Diseases in Adulthood.
PMID: 31441727 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - August 22, 2019 Category: Drugs & Pharmacology Authors: Briana DD, Malamitsi-Puchner A Tags: Curr Vasc Pharmacol Source Type: research

Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Talking Face to Face is Better than a Phone Call.
PMID: 31433760 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - August 19, 2019 Category: Drugs & Pharmacology Authors: Metzinger-Le Meuth V, Metzinger L Tags: Curr Vasc Pharmacol Source Type: research

What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. Its prevalence is increasing because of obesity, metabolic syndrome or Type 2 Diabetes Mellitus (T2DM). NAFLD can cause liver inflammation and progress to Non-Alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis or Hepatocellular Cancer (HCC). Nevertheless, Cardiovascular Disease (CVD) is the most common cause of morbidity and mortality in NAFLD/NASH patients. Current guidelines suggest the use of p...
Source: Current Vascular Pharmacology - August 17, 2019 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos K, Stavropoulos K, Athyros VG Tags: Curr Vasc Pharmacol Source Type: research

Insulin Therapy, Insulin Resistance and Vascular Dysfunction.
via L Abstract PMID: 31418345 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - August 17, 2019 Category: Drugs & Pharmacology Authors: Vázquez MC, Sobrevia L Tags: Curr Vasc Pharmacol Source Type: research

Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement.
Nordestgaard BG Abstract PMID: 31418346 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - August 17, 2019 Category: Drugs & Pharmacology Authors: Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG Tags: Curr Vasc Pharmacol Source Type: research

Prime Time for Lower Extremity Artery Disease
PMID: 31339024 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - July 23, 2019 Category: Drugs & Pharmacology Authors: De Carlo M Tags: Curr Vasc Pharmacol Source Type: research

Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review
N, Nordestgaard Abstract Postprandial hypertriglyceridaemia, defined as an increase in plasma triglyceride-containing lipoproteins following a fat meal, is a potential risk predictor of atherosclerotic cardiovascular disease and other chronic diseases. Several non-modifiable factors (genetics, age, sex and menopausal status) and lifestyle factors (diet, physical activity, smoking status, obesity, alcohol and medication use) may influence postprandial hypertriglyceridaemia. This narrative review considers the studies published over the last decade that evaluated postprandial hypertriglyceridaemia. Additionally, th...
Source: Current Vascular Pharmacology - July 14, 2019 Category: Drugs & Pharmacology Authors: Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard Tags: Curr Vasc Pharmacol Source Type: research

Rhizoma Coptidis for Alzheimer's Disease and Vascular Dementia: A Literature Review.
Abstract BACKGROUND: Alzheimer's disease (AD) and vascular dementia (VaD) are major types of dementia, which both cause heavy economic burdens for families and society. However, no currently available medicines can control dementia progression. Rhizoma Coptidis, a Chinese herbal medicine, has been used for>2000 years, and is now gaining attention as a potential treatment for AD and VaD. METHODS: We reviewed the mechanisms of the active ingredients of Rhizoma Coptidis and Rhizoma Coptidis-containing Chinese herbal compounds in the treatment of AD and VaD. We focused on studies on ameliorating the risk facto...
Source: Current Vascular Pharmacology - July 9, 2019 Category: Drugs & Pharmacology Authors: Wang Z, Yang Y, Liu M, Wei Y, Liu J, Pei H, Li H Tags: Curr Vasc Pharmacol Source Type: research

Inhibition of miR-223 expression using a sponge strategy decreases restenosis in rat injured carotids.
CONCLUSIONS: Down-regulating miR-223 could be a potential therapeutic approach to prevent restenosis after angioplasty. PMID: 31284864 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - July 4, 2019 Category: Drugs & Pharmacology Authors: M'baya-Moutoula E, Marchand A, Six I, Bahrar N, Celic T, Mougenot N, Maitrias P, Massy ZA, Lompreh AM, Metzinger L, Meuth VM Tags: Curr Vasc Pharmacol Source Type: research

Uncaria rhynchophylla and Its Major Constituents on Central Nervous System: A Review on Their Pharmacological Actions.
CONCLUSION: U. rhynchophylla and its major components possess multiple beneficial pharmacological actions on CNS. Futher studies on U. rhynchophylla and its major components are warranted to fully illustrate the underlying molecular mechanisms, pharmacokinetics, and toxicological profiles of these naturally occurring compounds and their potential for clinical application. PMID: 31272356 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - July 2, 2019 Category: Drugs & Pharmacology Authors: Yang W, Ip SP, Liu L, Xian YF, Lin ZX Tags: Curr Vasc Pharmacol Source Type: research

Comment on Patient Adherence to Novel Oral Anticoagulants (NOACs) for the Treatment of Atrial Fibrillation and Occurrence of Associated Bleeding Events: A Systematic Review and Meta-analysis.
Abstract PMID: 31218946 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - June 21, 2019 Category: Drugs & Pharmacology Authors: Albert V, Arnet I, Gudka S Tags: Curr Vasc Pharmacol Source Type: research

Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial.
ve; P Abstract BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor is recommended for at least 12 months in patients after an acute coronary syndrome (ACS). However, its underuse and premature discontinuation is common in clinical practice. We aimed to investigate the impact of a dedicated follow-up strategy with clinical visits and counseling on adherence levels to ticagrelor in patients after ACS. METHODS: The PROGRESS is a prospective, randomized trial enrolling 400 ACS patients treated with ticagrelor. Patients were randomized to be followed-up in a dedicated outpatient clinic (In-per...
Source: Current Vascular Pharmacology - May 23, 2019 Category: Drugs & Pharmacology Authors: Crisci M, Gragnano F, Di Maio M, Diana V, Moscarella E, Pariggiano I, Di Maio D, Concilio C, Taglialatela V, Fimiani F, Cesaro A, Cirillo PL, Calabrò P Tags: Curr Vasc Pharmacol Source Type: research

Treatment of Diabetic Cardiovascular Autonomic, peripheral and painful neuropathy. Focus on the treatment of Cardiovascular Autonomic Neuropathy with ACE inhibitors.
Abstract Neuropathies of the peripheral and autonomic nervous systems affect up to half of all people with diabetes mellitus, and are major risk factors for foot ulceration, amputation and cardiovascular dysfunction. Peripheral neuropathies manifest with either painful or painless symptoms, but many patients experience both. Once diagnosed appropriately, painful diabetic neuropathy management presents a unique challenge for physicians and should be considered as a syndrome, clinically distinct from diabetic peripheral neuropathy. The aetiology is multifactorial: metabolic changes in diabetes may directly affect ne...
Source: Current Vascular Pharmacology - May 19, 2019 Category: Drugs & Pharmacology Authors: Didangelos T, Veves A Tags: Curr Vasc Pharmacol Source Type: research

Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement
Nordestgaard BG PMID: 31104396 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 16, 2019 Category: Drugs & Pharmacology Authors: Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG Tags: Curr Vasc Pharmacol Source Type: research

Insulin Therapy, Insulin Resistance and Vascular Dysfunction
via L PMID: 31079435 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 12, 2019 Category: Drugs & Pharmacology Authors: Vázquez MC, Sobrevia L Tags: Curr Vasc Pharmacol Source Type: research

Postprandial Hypertriglyceridaemia Revisited In The Era Of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement.
Nordestgaard BG Abstract Residual vascular risk exists despite aggressive lowering of low density lipoprotein cholesterol (LDL-C). A contributor to this residual risk may be elevated fasting, or non-fasting, levels of triglyceride (TG)-rich lipoproteins. Therefore, there is a need to establish whether a standardised oral fat tolerance test (OFTT) can improve atherosclerotic cardiovascular (CV) disease (ASCVD) risk prediction in addition to a fasting or non-fasting lipid profile. An expert panel considered the role of postprandial hypertriglyceridaemia (as represented by an OFTT) in predicting ASCVD. The panel upd...
Source: Current Vascular Pharmacology - May 6, 2019 Category: Drugs & Pharmacology Authors: Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG Tags: Curr Vasc Pharmacol Source Type: research

Advanced Glycation End Products in Chinese Medicine Mediated Aging Diseases: A Review.
Abstract Aging has become a worldwide problem. During this process, incidence of related diseases such as diabetes and atherosclerosis increases dramatically. Studies within most recent two decades suggest pivotal role of advanced glycation end products (AGEs) in aging process. This review aims to systemically summarize effects and potential mechanism of Chinese Medicines on inhibiting AGEs-related aging diseases. PMID: 31060489 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 6, 2019 Category: Drugs & Pharmacology Authors: Zhang W, Zhao T, Zhao Y, Gui D, Xu Y Tags: Curr Vasc Pharmacol Source Type: research

Complementary and Alternative Medicine for the Treatment of Insomnia: An Overview of Scientific Evidence from 2008 to 2018.
Abstract Insomnia is a widespread sleep disorder in the general population, and it is a risk factor for impaired function, the development of other medical and mental disorders, and increase health care costs. In view of the health hazards of insomnia and the shortcomings of western medicine, complementary and alternative medicine (CAM) should be considered in the management of insomnia. The present overview reports the potential role of herbal medicine and non-pharmacological therapies in the treatment of insomnia and summarizes the scientific evidence reported from 2008 to 2018. PubMed and Web of Science databas...
Source: Current Vascular Pharmacology - May 5, 2019 Category: Drugs & Pharmacology Authors: Cheng B, Liu Y, Tian J, Gao R, Liu Y Tags: Curr Vasc Pharmacol Source Type: research

Microvascular complications of type 2 diabetes mellitus.
CONCLUSION: Early detection of microvascular complications is of great importance, as early intervention leads to better outcomes, but requires awareness of their definition, prevalence and diagnostic modalities. PMID: 31057114 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 30, 2019 Category: Drugs & Pharmacology Authors: Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K Tags: Curr Vasc Pharmacol Source Type: research

Pre- and Post-conditioning in Cardiovascular Surgery
PMID: 31030481 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 28, 2019 Category: Drugs & Pharmacology Authors: Guerrero OJL, Ramirez Tags: Curr Vasc Pharmacol Source Type: research

Response on Patient Adherence to Novel Oral Anticoagulants (NOACs) for the Treatment of Atrial Fibrillation and Occurrence of Associated Bleeding Events: A Systematic Review and Meta-analysis
PMID: 31030502 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 28, 2019 Category: Drugs & Pharmacology Authors: Shehab, Bhagavathula AS, Abebe TB, Abegaz TM, Elnour AA, Sabbour HM, Uzzafer M, Ahmad H, Hamad AK Tags: Curr Vasc Pharmacol Source Type: research

Arterial Stiffness, Cognitive Dysfunction, and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?
Abstract The incidence of hypertension (HTN) and its cardiovascular (CV) complications are increasing throughout the world. Blood pressure (BP) control remains unsatisfactory worldwide. Medical inertia and poor adherence to treatment are among the factors that can partially explain, why BP control rate remains low. The introduction of a method for measuring the degree of adherence to a given medication is now a prerequisite. Complex treatment regimes, inadequate tolerance and frequent replacements of pharmaceutical formulations are the most common causes of poor adherence. In contrast, the use of stable combinatio...
Source: Current Vascular Pharmacology - April 14, 2019 Category: Drugs & Pharmacology Authors: Kalaitzidis RG, Panagiotopoulou T, Stagikas D, Pappas K, Mpalafa O, Elisaf MS Tags: Curr Vasc Pharmacol Source Type: research

Diabetes and heart failure: Is it hyperglycemia or hyperinsulinemia?
Abstract The cardiac effects of exogenously administered insulin for the treatment of diabetes (DM) have recently attracted much attention. In particular, it has been questioned whether insulin is the appropriate treatment for patients with type 2 diabetes mellitus (T2DM) and heart failure. While several old and some new studies suggested that insulin treatment has beneficial effects for the heart, recent observational studies indicate associations of insulin treatment with increased risk of developing or worsening of a pre-existing heart failure and higher mortality rates. However, there is actually little eviden...
Source: Current Vascular Pharmacology - April 7, 2019 Category: Drugs & Pharmacology Authors: Didangelos T, Kantartzis K Tags: Curr Vasc Pharmacol Source Type: research

Management and Outcomes of Aortic Dissection in Pregnancy with Marfan syndrome: A Systematic Review.
CONCLUSIONS: Women with MFS are at high risk of aortic dissection during pregnancy and women with aortic root 41-45 mm should consider avoiding pregnancy. Guideline-specific management of aortic aneurysms in pregnancy will reduce the risk of dissection. Diagnosis and Management of MFS needs a multidisciplinary approach and team that should start working early in pregnancy. Further studies are needed to optimize medical and surgical approaches in addition to preconception counselling in high risk subjects. PMID: 30963974 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 7, 2019 Category: Drugs & Pharmacology Authors: Al-Thani H, Mekkodathil A, El-Menyar A Tags: Curr Vasc Pharmacol Source Type: research

The incidence of adverse drug reactions in patients treated with statins in the Emirates: a retrospective cohort study.
CONCLUSION: The incidence of ADRs among statin users was 42.6%, and frequent ADRs (49%) were noted in patients with high CVD risk. Early identification of these ADRs should improve patient adherence to life-saving statin treatment. PMID: 30963975 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 7, 2019 Category: Drugs & Pharmacology Authors: Shehab A, Bhagavathula AS, Elnour AA, Al-Rasadi K, Al-Shamsi S Tags: Curr Vasc Pharmacol Source Type: research

Calcium and vitamin D supplementation. Myths and realities with regard to cardiovascular risk.
Abstract Vitamin D and calcium are considered crucial for the treatment of bone diseases. Both vitamin D and calcium contribute to bone homeostasis but also preserve muscle health by reducing the risk of falls and fractures. Low vitamin D concentrations result in secondary hyperparathyroidism and contribute to bone loss, although the development of secondary hyperparathyroidism varies, even in patients with severe vitamin D deficiency. Findings from observational studies have shown controversial results regarding to the association between bone mineral density and vitamin D/calcium status, thus sparking a debate r...
Source: Current Vascular Pharmacology - April 7, 2019 Category: Drugs & Pharmacology Authors: Muscogiuri G, Barrea L, Altieri B, Di Somma C, Bhattoa H, Laudisio D, Duval GT, Pugliese G, Annweiler C, Orio F, Fakhouri H, Savastano S, Colao A Tags: Curr Vasc Pharmacol Source Type: research

Advances in dermoepidermal skin substitutes for diabetic foot ulcers.
;nez JL, Kakagia D, Papanas N Abstract Diabetic foot ulcers (DFUs) are one of the major complications of diabetes, representing a leading cause of hospitalisation and non-traumatic lower limb amputations. Multidisciplinary management, patient education, glucose control, debridement, off-loading, infection control, and adequate perfusion are the mainstays of standard care. Despite all these, at least 30% of DFUs fail to heal within 20 weeks. Therefore, dermoepidermal skin substitutes (DSS) have been used as a new therapeutic adjunct for DFUs. This brief review outlines the recent advances in DSS for the treatment o...
Source: Current Vascular Pharmacology - April 7, 2019 Category: Drugs & Pharmacology Authors: Álvaro-Afonso FJ, García-Álvarez Y, Lázaro-Martínez JL, Kakagia D, Papanas N Tags: Curr Vasc Pharmacol Source Type: research

Macrovascular complications of type 2 diabetes mellitus.
CONCLUSION: T2DM causes a variety of macrovascular complications through different pathogenetic pathways that include hyperglycaemia and insulin resistance. The association between T2DM and cardiovascular disease is clear, but we need more clinical studies in order to identify the pure effect of T2DM. PMID: 30961498 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 4, 2019 Category: Drugs & Pharmacology Authors: Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T Tags: Curr Vasc Pharmacol Source Type: research

Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block.
CONCLUSIONS: Newer antidiabetic drugs (SPPARMs, GLP-1 RA and SGLT2i) alone or in combination and acting alone or on the background of potent statin therapy which is recommended in T2DM, might contribute substantially to NAFLD/NASH amelioration, possibly reducing not only liver specific but also cardiovascular morbidity. These observations warrant long term placebo controlled randomized trials with appropriate power and outcomes, focusing on the general population and more specifically on T2DM with NAFLD/NASH. Certain statins may be useful for treating NAFLD/NASH, while they substantially reduce cardiovascular disease risk....
Source: Current Vascular Pharmacology - April 4, 2019 Category: Drugs & Pharmacology Authors: Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS Tags: Curr Vasc Pharmacol Source Type: research

Pharmacological Management of Diabetic Nephropathy.
CONCLUSION: RAS inhibitors, SGLT-2i and GLP-1 agonists were found to be beneficial for the treatment of DN. Larger renal trials are needed in order to incorporate these drugs into the first line treatment of DN. PMID: 30961500 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 4, 2019 Category: Drugs & Pharmacology Authors: Papademetriou V, Alataki S, Stavropoulos K, Papadopoulos C, Bakogiannis K, Tsioufis K Tags: Curr Vasc Pharmacol Source Type: research

The Growing Epidemic Of Diabetes Mellitus.
CONCLUSION: Having recognized the global burden of DM, we now realize the urgent need for effective interventions. In order to monitor the public-health strategies and design effective future interventions we need reliable global estimates regarding the prevalence of DM. PMID: 30961501 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 4, 2019 Category: Drugs & Pharmacology Authors: Lovic D, Piperidou A, Zografou I, Grassos H, Pittaras A, Manolis A Tags: Curr Vasc Pharmacol Source Type: research

Diabetes Mellitus and Acute Coronary Syndrome: A Lethal Combination Requiring Better Therapeutic Strategies.
PMID: 30919778 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 26, 2019 Category: Drugs & Pharmacology Authors: Katsiki N, Papanas N Tags: Curr Vasc Pharmacol Source Type: research

Hypertriglyceridemia: An Infrequent, Difficult-to-Predict, Severe Metabolic and Vascular Problem Associated with Estrogen Administration.
Abstract Supplementary estrogen plays important roles for female patients as convenient birth control, relief of postmenopausal symptoms, and in management of other selected problems. However, as is the case for essentially all medications, there are side effects. Short of a major pulmonary embolus, the most severe side effect of estrogen would appear to be sporadic, rare, and severe hypertriglyceridemia associated with acute pancreatitis. The occurrence of this fortunately rare problem usually happens in the presence of some preexisting and usually mild increase in triglycerides (TG). A case of chronic and severe...
Source: Current Vascular Pharmacology - March 4, 2019 Category: Drugs & Pharmacology Authors: Whayne TF Tags: Curr Vasc Pharmacol Source Type: research